CervoMed Inc. CRVO
1.55 USD -0.09 (-5.49%)
At closeNov 3, 2026, 4:07 PM EST
1.54 -0.01 -0.65%
After hours · Nov 3, 4:07 PM ET
1.52 Day range 1.70
1.52 52-week range 10.00
- YTD
- -80.38%
- 1 year
- -77.92%
News
globenewswire.com CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) Placebo-controlled results of RewinD-LB clinical trial published in Alzheimer's Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 million. XORTX Therapeutics…
benzinga.com CervoMed Shows Progress in Treating Rare Aphasia Condition CervoMed Inc. (NASDAQ:CRVO) reported early results from its Phase 2a clinical study evaluating neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA).
benzinga.com CervoMed Shows Progress in Treating Rare Aphasia Condition CervoMed reports a promising reduction in neuronal damage biomarkers during the first 12 weeks of its Phase 2a trial for neflamapimod.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…
benzinga.com CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) announced initial data showing a reduction in mean plasma levels of neurofilament light chain (NfL), a key biomarker of neuronal damage and…
defenseworld.net CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright CervoMed (NASDAQ: CRVO - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Monday, MarketBeat reports. A number of other…
benzinga.com HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
defenseworld.net CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages CervoMed Inc. (NASDAQ: CRVO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One research…
globenewswire.com CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience
globenewswire.com CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),…
benzinga.com CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting 12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual MeetingnfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with…
globenewswire.com CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
globenewswire.com CervoMed to Participate in September Investor Conferences BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"),…- benzinga.com HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
benzinga.com Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18 Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.- benzinga.com CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.60) by 6.67 percent. This is a 8.57 percent increase over losses of $(0.70)…
globenewswire.com CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United…
globenewswire.com CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today…
globenewswire.com CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB) Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
benzinga.com HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.- benzinga.com CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026 New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in "pure" DLB and support selection of 50 mg TID for planned Phase 3 study in…
globenewswire.com CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
benzinga.com HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
benzinga.com CervoMed Completes Enrollment In Phase 2A Study Of Neflamapimod For nfvPPA, Type Of Frontotemporal Dementia; First Biomarker Data Expected In Early Q4 Of 2026 And The First Clinical Data In Q1 2027 CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has completed enrollment…
globenewswire.com CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
globenewswire.com CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026 Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain…
globenewswire.com CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-market session. The company's market cap stands at $4.0 million. Aditxt (NASDAQ:ADTX) shares rose 84.99% to…- benzinga.com CervoMed Agreed To Raise $10M in Direct Stock Offering Of 2.5M Shares At $4/Share, Plans to Use Stock Sale Proceeds for Working Capital On June 18, 2026, CervoMed Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with the investors named therein (the
- benzinga.com CervoMed Announces $10M Registered Direct Offering Of 2.5M Shares At $4/Share To Fund Working Capital And General Corporate Purposes CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into…
globenewswire.com CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com CervoMed Receives U.S. Patent For Its Neflamapimod Drug Candidate For The Treatment Of Dementia With Lewy Bodies CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of…
globenewswire.com CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042 BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com CORRECTION: Reported June 15, 2026: CervoMed Form4 Filing Shows Director Joshua S. Boger Acquired ~2.87M Share-Equivalent Position Via $3.14/Unit Private Placement (955,414 Shares Plus Matching Series B and C Warrants); Holds 20% Position As Of June 11, 2026 Explanation of Responses:1. On June 11, 2026, the Issuer completed a private placement (the "Private Placement") pursuant to a securities purchase agreement, dated June 9, 2026 (the "Purchase…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
globenewswire.com CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com CervoMed Announces Private Placement With Expected Gross Proceeds Of ~$10.5M; Will Extend Cash Runway Into Q2 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodiesAnticipated pipeline milestones over next six months include obtaining 24-week…
globenewswire.com CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies…
globenewswire.com CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies in second half of 2026, subject to financing
benzinga.com Alpha Buying: Managing Biotech Risk With Insider Clues - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session